Market Access Hurdles Under the New VA EHR Deployment

Bottom Line:

The VA's accelerated EHR deployment is centralizing clinical decisions. To preserve market access, commercial teams must prove how their therapies reduce operational friction within this standardized baseline.

The recent deployment of the Department of Veteran Affairs (VA) Federal Electronic Health Record (EHR) system across its first wave of four hospitals in Michigan and its second wave of four hospitals in Ohio and Northern Kentucky marks a critical shift for pharmaceutical and medical device manufacturers. Under the accelerated schedule designed to bring thirteen sites live this year, the VA is making a highly visible, coordinated push toward system-wide uniformity. This pace highlights an agency-wide commitment to rapid, multi-state expansion. Manufacturers must revise any pre-existing view of these rollouts as isolated IT upgrades and see them as a systemic realignment that will ultimately dictate market access across the entire nation. For commercial teams, this centralized governance means that national account strategies must be sharper.

Understanding this shifting architecture requires recognizing how the federal ecosystem diverges from traditional commercial markets with its new top-down approach enforced by the EHR. With this deployment, the VA EHR systematically dismantles fragmentation by embedding standardized clinical protocols directly into the software interface, restricting customized order sets. While the operational intent of this standardization is to support high-volume, first-line, and common care pathways, it is not designed to cover every clinical scenario, which is where exception pathways remain both necessary and legitimate.

Rather than viewing these rigid national standards as an impenetrable barrier, manufacturers should recognize them as a manageable path for faster, data-driven adoption at a national scale. When a manufacturer successfully aligns its clinical data with the centralized national standard, the top-down nature of the EHR allows for rapid, system-wide utilization. By demonstrating that a product reduces administrative burden, simplifies dosing protocol compliance, or prevents complications that disrupt standardized care pathways, manufacturers align themselves directly with the VA’s overarching goals.

Value propositions must be translated directly into the language of the EHR baseline. The presentation of evidence by sales forces is crucial to illustrate how therapies can decrease workflow friction for clinicians, lower the risk of adverse events that complicate standardized care pathways, and streamline patient transitions across facilities. By framing therapeutics as operational solutions that facilitate uniform patient care, pharmaceutical manufacturers can successfully secure long-term market access in this newly standardized federal landscape.